Frequently Asked Questions

Below are answers to the questions we hear most often. Still curious? Contact us!

General

1. What is Anubis BioConsulting?
We exist because too many life sciences investment decisions are made on narrative rather than evidence, and too many great science companies stall at the capital interface. We're not a generalist strategy firm with a science vertical; we're scientists who learned the capital side. We help science-driven companies raise capital, navigate regulation, and build products, and we help investors evaluate life sciences opportunities with technical rigor.

2. Who do you typically work with?
Two groups: (1) science-driven companies — startups, founders, and small biotech, medtech, and pharma firms; and (2) private equity firms, VCs, and investors assessing life sciences deals.

3. Who actually does the work?
Engagements are led by our core team and supported by a trusted network of specialists: financial advisors, science and technology experts, scientific writers, medtech and IT experts, and regulatory advisors, among others. We assemble the right mix for each project rather than forcing a one-size-fits-all team.

4. What areas do you cover?
Our team's background spans immunology, medtech, neurosciences, and oncology. Through past engagements, we've also worked across bioinformatics, computational biology, diagnostics, food technology, environmental sciences, and ESG — and we tap our expert network to extend into adjacent areas as needed.

5. Where are you based, and do you work internationally?
We operate across the US and EU and support clients globally.

For Companies

6. What services do you offer to biotech, medtech, and pharma startups?
Strategy and roadmapping, clinical and regulatory pathway design, FDA/EMA submissions, grant writing, IP strategy, and investor-ready pitch decks.

7. Can you help us write grant applications?
Yes. We develop grant applications, including SBIR/STTR, R21, R01, and DOD submissions, among others. We've worked on grant applications across bioinformatics, oncology, biology, and environmental sciences.

8. Can you help us prepare a pitch deck for investors?
Absolutely. We build investor-ready pitch decks grounded in scientific rigor and aligned to what life sciences investors actually want to see. Recent work includes pitch decks and fundraising support across environmental science, bioinformatics, diagnostics, and oncology.

For Investors

9. What does your due diligence service include?
Competitive intelligence, market analysis, IP review, regulatory navigation, technology assessment, and identification of KOLs and domain specialists. We've delivered due diligence across sectors ranging from oncology to textile recycling, along with ESG and legal case reports focused on health and environment.

10. Why use Anubis BioConsulting instead of a generalist firm?
We bring strong scientific and technological understanding to the investment process, so decisions are based on evidence, not just narrative.

11. Do you have access to subject-matter experts and KOLs?
Yes. We maintain a trusted network of Key Opinion Leaders (KOLs) and domain specialists we can mobilize per engagement.

Process & Engagement

12. How do engagements start, and how long do they take?
With a free intro chat: email info@anubisbc.com or fill out our contact form. Project length varies, from short-term due diligence sprints to multi-month regulatory and fundraising engagements; we scope timelines during the initial conversation.

13. How are your services priced?
Pricing depends on scope, complexity, and duration. We also consider alternative payment structures on a case-by-case basis, and provide tailored proposals after the initial consultation.

14. Do you sign NDAs?
Yes: confidentiality is standard practice on every engagement. We use NDAs tailored to each project and reviewed by our legal team to ensure balanced, appropriate terms for both sides.

This FAQ is provided for informational purposes only and does not constitute a contract, offer, or legal advice. Specific terms of engagement, including confidentiality and payment, are set out in individual signed agreements.